The effect of statin therapy on ventricular tachyarrhythmias: A meta-analysis

American Journal of Therapeutics

Volumn 19, Issue 1, 2012, Pages 16-23

  Wanahita, Nikolas ^a   Chen, Jennifer ^b,c   Bangalore, Sripal ^d   Shah, Kunal ^a   Rachko, Maurice ^a   Coleman, Craig I ^b,c   Schweitzer, Paul ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

meta analysis; statins; ventricular arrhythmias

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ARTICLE; CARDIOMYOPATHY; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; DATA BASE; DEFIBRILLATOR; DRUG EFFECT; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL;

AGED; CARDIOMYOPATHIES; CORONARY ARTERY DISEASE; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 84855660076     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181e9087a     Document Type: Article

References (39)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996:335:1001-1009. (Pubitemid 26338729)
3. Shepherd J, Cobbe SM, Ford I, et al; for the West Scotland Coronary Prevention Study Group (WOSCOPS). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1308.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
5. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006;98: S18-S25. (Pubitemid 44779497)
6. Almuti K, Rimawi R, Spevack D, et al. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006;109:7-15.
7. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650. (Pubitemid 28248591)
8. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18. (Pubitemid 35247880)
9. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with averaged cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844. (Pubitemid 28397432)
10. Mozaffarian D, Minami E, Letterer RA, et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005;96:1699-1704. (Pubitemid 41790394)
11. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233. (Pubitemid 29293431)
12. Tousoulis D, Antoniades C, Vassiliadou C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail. 2005;7:1126-1132. (Pubitemid 41721115)
13. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. 2000;36:766-772.
14. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) Study. Circulation. 2006;114:1455-1461. (Pubitemid 44526999)
15. Fauchier L, Pierre B, De Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation: a metaanalysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828-835. (Pubitemid 351255618)
16. De Sutter J, Firsovaite V, Tavernier R. Prevention of sudden death in patients with coronary artery disease: do lipid lowering drugs play a role? Prev Cardiol. 2002;5:177-182. (Pubitemid 35283510)
17. Bradburn MJ, Deek JJ, Altman DG. Sbe24: metan-an alternative meta-analysis command. Stata Technical Bulletin Reprints. 1998;8:86-100.
18. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-894.
19. Kayikcioglu M, Can L, Evrengul H, et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol. 2003;90:63-72. (Pubitemid 36734844)
20. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy in risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol. 2005;95:490-491. (Pubitemid 40247545)
21. Riahi S, Schmidt EB, Christensen JH, et al. Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease. Cardiology. 2005;104:210-214. (Pubitemid 41407277)
22. Fonarow GC, Wright RS, Spencer FA, et al; for the National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611-616. (Pubitemid 41207298)
23. Vyas AK, Guo H, Moss AJ, et al; for the MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator impaction trial. J Am Coll Cardiol. 2006;47:769-763.
24. Mitchell LB, Powell JL, Gillis AM, et al; and the AVID investigators. Are lipid-lowering drugs also antiarrhythmic drugs? J Am Coll Cardiol. 2003;42:81-87.
25. Coleman CI, Kluger J, Bhavnani S, et al. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. Heart Rhythm. 2008;5:507-510.
26. Goldberger JJ, Subacius H, Schaechter A, et al; for the DEFINITE Investigators. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006; 48:1228-1233. (Pubitemid 44363151)
27. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
28. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:425-426.
29. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-337. (Pubitemid 43063250)
30. Bleske BE, Nicklas JM, Bard RL, et al. Neutral effects on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMGCoA reductase inhibition in non-diabetic patients with nonsichemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol. 2006;47:338-341. (Pubitemid 43063251)
31. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719-731. (Pubitemid 36399228)
32. Sun W, Lee TS, Zhu M, et al. Statins activate AMPactivated protein kinase in vitro and in vivo. Circulation. 2006;114:2655-2662. (Pubitemid 44967349)
33. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005;97:1232-1235.
34. Owlya R, Vollenweider L, Trueb L, et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation. 1997;96: 3897-3903.
35. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail. 2005;11:684-690. (Pubitemid 41797497)
36. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation. 2004; 109:2234-2239. (Pubitemid 38625402)
37. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2a formation. J Cardiovasc Pharmacol. 2002;40:868-874.
38. Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation. 2002;106: 2118-2124. (Pubitemid 35192819)
39. Martin J, Denver R, Bailey M, et al. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Clin Exp Pharmacol Physiol. 2005:32:697-701. (Pubitemid 41603148)